2023
Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia
Blette B, Granholm A, Li F, Shankar-Hari M, Lange T, Munch M, Møller M, Perner A, Harhay M. Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. Scientific Reports 2023, 13: 6570. PMID: 37085591, PMCID: PMC10120498, DOI: 10.1038/s41598-023-33425-3.Peer-Reviewed Original ResearchConceptsCritical COVID-19Better long-term outcomesCOVID-19Entire trial populationStandardized dosing protocolsMultiple patient characteristicsDose of dexamethasoneLong-term outcomesIL-6 inhibitorsDexamethasone doseSevere hypoxemiaMost patientsPatient characteristicsRespiratory supportDiabetes mellitusClinical outcomesDosing protocolTrial populationTreatment effect heterogeneityPatient featuresPatientsAdditional studiesDexamethasoneDoseMore evidence
2021
Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19
Nugent J, Aklilu A, Yamamoto Y, Simonov M, Li F, Biswas A, Ghazi L, Greenberg J, Mansour S, Moledina D, Wilson FP. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. JAMA Network Open 2021, 4: e211095. PMID: 33688965, PMCID: PMC7948062, DOI: 10.1001/jamanetworkopen.2021.1095.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedAged, 80 and overBlack or African AmericanCohort StudiesComorbidityCOVID-19CreatinineFemaleFollow-Up StudiesGlomerular Filtration RateHispanic or LatinoHumansHypertensionKidney Function TestsLongitudinal StudiesMaleMiddle AgedPatient DischargeProportional Hazards ModelsRenal Insufficiency, ChronicRetrospective StudiesSARS-CoV-2United StatesConceptsCOVID-19-associated acute kidney injuryAcute kidney injuryHospital acute kidney injurySubgroup of patientsKidney functionKidney injuryCohort studyHospital dischargeAKI recoveryKidney diseaseCOVID-19Peak creatinine levelsRetrospective cohort studyChronic kidney diseaseDays of dischargeHalf of patientsGlomerular filtration rateCoronavirus disease 2019AKI severityBaseline comorbiditiesEGFR decreaseDialysis requirementEGFR slopeKidney recoveryCreatinine levels
2020
An evidence mapping and analysis of registered COVID-19 clinical trials in China
Lu L, Li F, Wen H, Ge S, Zeng J, Luo W, Wang L, Tang C, Xu N. An evidence mapping and analysis of registered COVID-19 clinical trials in China. BMC Medicine 2020, 18: 167. PMID: 32493331, PMCID: PMC7268588, DOI: 10.1186/s12916-020-01612-y.Peer-Reviewed Original ResearchConceptsCOVID-19 clinical trialsCurrent Control TrialsClinical Trials RegistryNational Research RegisterTraditional Chinese medicinePrimary outcomeTrials RegistryClinical trialsAntiviral drugsCOVID-19 nucleic acid testInternational Clinical Trials Registry PlatformAustralian Clinical Trials RegistryClinical Trials Registry PlatformChinese Clinical Trial RegistryEvidence mappingPilot studyPhase 4 trialTrials Registry PlatformNucleic acid testCOVID-19 trialsData monitoring committeePublic Health DivisionMedian sample sizeBiological agentsType of intervention